Bromo DragonFLY (DOB-DragonFLY) also known as b or Dragonfly is a synthetic psychedelic substance of the substituted amphetamine and phenethylamine chemical classes. It produces an array of extremely dose-sensitive psychedelic effects when administered. It was first synthesized in 1998 by Matthew Parker from DOB-FLY.
Bromo-DragonFLY is extremely poBromo-DragonFLY (or 3C-Bromo-Dragonfly, DOB-Dragonfly) is a psychedelic drug related to the phenethylamine family. Bromo-DragonFLY is considered a potent hallucinogen, having around one third the potency of LSD with a normal dose in the region of 200 μg to 800 μg,and it has an extremely long duration of action, up to several days. Bromo-DragonFLY has a stereocenter and (R)-(−)-bromo-DragonFLY is the more active stereoisomer.tent and produces unusually long effects which reportedly can last up to several days. It is considered to have one-third the potency of LSD by weight, making it remarkably potent relative to the vast majority of psychedelics.
Due to its high potency and unpredictable dose-response, many reports indicate that the effects of this substance may end up being overly difficult to use safely for those who are not already experienced with hallucinogens. Specifically, given that the dosage and duration of this substance have yet not been fully determined, users are advised to start at the lowest possible, intake only through the oral routes of administration, and never re-dose during any time throughout the experience.
Very little is known about the pharmacology, metabolism and toxicity about It in humans. It briefly gained popularity among research chemicals circa 2010 until several deaths occurred after the substance was accidentally mislabeled and sold as 2C-B-FLY, leading to its prohibition.
The hallucinogenic effect of it is mediated by its agonist activity at the 5-HT2A serotonin receptor. It also has a high binding affinity for the 5-HT2B and 5-HT2C serotonin receptors, and is most accurately described as a non-subtype selective 5-HT2 agonist, as it is actually twice as potent an agonist for 5-HT2C receptors as for 5-HT2A, as well as being less than 5x selective for 5-HT2A over 5-HT2B. Bromo-DragonFLY is also a MAO-A inhibitor, and thus strongly inhibits oxidative deamination of 5-HT, increasing its risk profile.
Bromo-DragonFLY has never been documented as being sold on the street and has seemingly stopped production on research chemicals gray market. Due to its novelty and extremely short history of human usage, all information related to the use of this compound should be received with extreme caution. It is strongly recommended that one use the utmost harm reduction practices if choosing to take this substance.
The typical dose of Bromo-DragonFLY is not known, however it has varied from 500 μg to 1 mg. It has about 300 times the potency of mescaline, or 1/3 the potency of LSD. It has been sold in the form of blotters, similar to the distribution method of LSD, which has led to confusion and reports of mistakenly consuming Bromo-DragonFly. It has a much longer duration of action than LSD and can last for up to 2–3 days following a single large dose, with a slow onset of action that can take up to 6 hours before the effects are felt.